Psychopharmacology in the treatment of irritable bowel syndrome

Primary Psychiatry

Volumn 14, Issue 4, 2007, Pages 40-50

  Lydiard, R Bruce ^a,b  

^a Southeast Health Consultants LLC   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMFEBUTAMONE; AMITRIPTYLINE; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MIRTAZAPINE; MOOD STABILIZER; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GASTROINTESTINAL ABSORPTION; GENERALIZED ANXIETY DISORDER; HUMAN; IRRITABLE COLON; LOW DRUG DOSE; MAJOR DEPRESSION; NAUSEA; NERVOUSNESS; PANIC; PATIENT SATISFACTION; POSTTRAUMATIC STRESS DISORDER; PRACTICE GUIDELINE; PSYCHOPHARMACOLOGY; REVIEW; SENSORY STIMULATION; SIDE EFFECT; SIGNAL TRANSDUCTION; SOMATOSENSORY STIMULATION; STRESS;

EID: 34248136461     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (71)

1. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology. 2002;123(6):2108-2131.
2. Irwin C, Falsetti SA, Lydiard RB, Ballenger JC, Brock CD, Brener W. Comorbidity of posttraumatic stress disorder and irritable bowel syndrome. J Clin Psychiatry. 1996;57(12):576-578.
3. Leserman J. Association of sexual and physical abuse with functional gastrointestinal and pelvic pain. Primary Psychiatry. 2007;14(4):58-63.
4. Jarcho JM, Mayer EA. Stress and irritable bowel syndrome. Primary Psychiatry. 2007;14(4):74-78.
5. Fresé MP, Naliboff BD. Stress and heartburn: a biobehavioral perspective. Primary Psychiatry. 2007;14(4):51-57.
6. Goddard ER, Barth KS, Lydiard RB. Disorders which frequently overlap with irritable bowel syndrome: can a shared neurobiology explain their frequent association? Primary Psychiatry. 2007;14(4):69-73.
7. Stam R, Akkermans LM, Wiegant VM. Trauma and the gut: interactions between stressful experience and intestinal function. Gut. 1997;40(6):704-709.
8. Bennett EJ, Tennant CC, Piesse C, Badcock CA, Kellow JE. Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut. 1998;43(2):256-261.
9. Posserud I, Agerforz P, Ekman R, Bjornsson ES, Abrahamsson H, Simren M. Altered visceral perceptual and neuroendocrine response in patients with irritable bowel syndrome during mental stress Gut. 2004;53(8):1102-1108.
10. Mayer EA, Naliboff BD, Chang L, Coutinho SV. V. Stress and irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2001;280(4):G519-G524.
11. Delvaux M. Role of visceral sensitivity in the pathophysiology of irritable bowel syndrome. Gut. 2002;51(suppl 1):i67-i71.
12. Charmandari E, Tsigos C, Chrousos G. Endocrinology of the stress response. Annu Rev Physiol. 2005;67:259-284.
13. Drossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy versus education and desipramine versus placebo for moderate to severe functional bowel disorders. Gastroenterology. 2003;125(1):19-31.
14. Lea R, Houghton LA, Calvert EL, et al. Gut-focused hypnotherapy normalizes disordered rectal sensitivity in patients with irritable bowel syndrome. Ailiment Pharmacol Ther. 2003;17(5):635-642.
15. Guthrie E, Barlow J, Fernandes L, et al. Changes in tolerance to rectal distension correlate with changes in psychological state in patients with severe irritable bowel syndrome. Psychosom Med. 2004;66(4):578-582.
16. Clouse RE, Lustman PJ. Use of psychopharmacological agents for functional gastrointestinal disorders. Gut. 2005;54(9):1332-1341.
17. Chang L. Neuroendocrine and neuroimmune markers in IBS: pathophysiological role or epiphenomenon? Gastroenterology. 2006;130(2):596-600.
18. Jackson JL, O'Malley PG, Tomkins G, Balden E, Santoro J, Kroenke K. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med. 2000;108(1):65-72.
19. Tanum L, Malt UF. A new pharmacologic treatment of functional gastrointestinal disorder. A doubleblind placebo controlled study with mianserin. Scand J Gastroenterol. 1996;31(4):318-325.
20. Brandt LJ, Bjorkman D, Fennerty MB, et al. Systematic review on the management of irritable bowel syndrome in North America. Am J Gastroenterol. 2002;97(suppl 11):S7-S26.
21. Irvine EJ, Whitehead WE, Chey WD, et al. Design of treatment trials for functional gastrointestinal disorders. Gastroenterology. 2006;130(5):1538-1551.
22. Jailwala J, Imperiale TF, Kroenke K. Pharmacologic treatment of the irritable bowel syndrome: a systematic review of randomized, controlled trials. Ann Intern Med. 2000;133(2):136-147.
23. Olden KW. The use of antidepressants in functional gastrointestinal disorders: new uses for old drugs. CNS Spectr. 2005;10(11):891-896.
24. Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol. 2003;1(3):219-228.
25. Tabas G, Beaves M, Wang J, Friday P, Mardini H, Arnold G. Paroxetine to treat irritable bowel syndrome not responding to high-fiber diet: a double-blind, placebo-controlled trial. Am J Gastroenterol. 2004;99(5):914-920.
26. Tack J, Broekaert D, Fischler B, Oudenhove LV, Gevers AM, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut. 2006;55(8):1095-1103.
27. Clouse RE, Lustman PJ, Geisman RA, Alpers DH. Antidepressant therapy in 138 patients with irritable bowel syndrome: a five-year clinical experience. Aliment Pharmacol Ther. 1994;8(4):409-416.
28. Masand PS, Gupta S, Schwartz TL, et al. Paroxetine in patients with irritable bowel syndrome: a pilot open-label study. Prim Care Companion J Clin Psychiatry. 2002;4(1):12-16.
29. Masand PS, Gupta S, Schwartz TL, Virk S, Hameed A, Kaplan DS. Open-label treatment with citalopram in patients with irritable bowel syndrome: a pilot study. Prim Care Companion J Clin Psychiatry. 2005;7(4):162-166.
30. Creed F, Fernandes L, Guthrie E, et al. The cost-effectiveness of psychotherapy and paroxetine for severe irritable bowel syndrome. Gastroenterology. 2003;124(2):303-317.
31. Morgan V, Pickens D, Gautam S, Kessler R, Mertz H. Amitriptyline reduces rectal pain related activation of the anterior cingulate cortex in patients with irritable bowel syndrome. Gut. 2005;54(5):601-607.
32. Tache Y, Martinez V, Million M, Wang L. Stress and the gastrointestinal tract III. Stress-related alterations of gut motor function: role of brain corticotropin-releasing factor receptors. Am J Physiol Gastrointest Liver Physiol. 2001;280(2):G173-G177.
33. Bueno L, Fioramonti J, Garcia-Villar R. Pathobiology of visceral pain: molecular mechanisms and therapeutic implications. III. Visceral afferent pathways: a source of new therapeutic targets for abdominal pain. Am J Physiol Gastrointest Liver Physiol. 2000;278(5):G670-G676.
34. Duman RS, Monteggia LM. A neurotrophic role for stress-related disorders. Biol Psychiatry. 2006;59(12):1116-1127.
35. Gershon MD. Neural injury, repair, and adaptation in the GI tract. V. Genes, lineages, and tissue interactions in the development of the enteric nervous system. Am J Physiol Gastrointest Liver Physiol. 1998;275(5):G869-G873.
36. McKewen BS. Mood disorders and allostatic load. Biol Psychiatry. 2003;54(3):200-207.
37. Charney DS. Psychobiological mechanisms of resilience and vulnerability: implications for successful adaptation to extreme stress. Am J Psychiatry. 2004;161(2):195-216.
38. Stout SC, Owens MJ, Nemeroff CB. Regulation of corticotropin-releasing factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic antidepressant treatment. J Pharmacol Exp Ther. 2002;300(3):1085-1092.
39. Castren E. Neurotrophins as mediators of drug effects on mood, addiction, and neuroprotection Mol Neurobiol. 2004;29(3):289-302.
40. Schafer M, Mousa SA, Stein C. Corticotropin-releasing factor in antinociception and inflammation. Eur J Pharmacol. 1997;323(1):1-10.
41. Nemeroff CB, Vale WW. The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry. 2005;66(suppl 7):5-13.
42. Owens MJ, Nemeroff CB. The role of corticotropin-releasing factor in the pathophysiology of affective and anxiety disorders: laboratory and clinical studies. Ciba Found Symp. 1993;172:296-308.
43. Dinan TG, Quigley EM, Ahmed SM, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology. 2006;130(2):304-311.
44. Gonsalkorale WM, Perrey C, Pravacia V, Whoraell PJ, Hutchinson IV. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut. 2003;52(1):91-93.
45. Moshiree B, Zhou Q, Price DD, Verne GN. Central sensitisation in visceral pain disorders. Gut. 2006;55(7):905-908.
46. Black PH. Stress and the inflammatory response: a review of neurogenic inflammation. Brain Behav Immun. 2002;16(6):622-653.
47. Charmandari E, Tsigos C, Chrousos G. Endocrinology of the stress response. Annu Rev Physiol. 2005;67:259-284.
48. Hayley S, Merali Z, Anisman H. Stress and cytokine-elicited neuroendocrine and neurotransmitter sensitization: implications for depressive illness. Stress. 2003;6(1):19-32.
49. Anisman H, Merali Z. Cytokines, stress and depressive illness: brain-immune interactions. Ann Med. 2003;35(1):2-11.
50. Kenis G, Maes M. Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol. 2001;5(4):401-412.
51. Kubera M, Lin AH, Kenis G, Bosmans E, van Bockstaele D, Maes M. Anti-inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio. J Clin Psychopharmacol. 2001;21(2):199-206.
52. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344(13):961-966.
53. Licinio J, Wong ML. The role of inflammatory mediators in the biology of major depression: central nervous system cytokines modulate the biological substrate of depressive symptoms, regulate stress-responsive systems, and contribute to neurotoxicity and neuroprotection. Mol Psychiatry. 1999;4(4):317-327.
54. O'Brien SM, Scott LV, Dinan TG. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum Psychopharmacol. 2004;19(6):397-403.
55. O'Brien SM, Scully P, Fitzgerald P, Scott LV, Dinan TG. Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res. 2007;41(3-4):326-331.
56. Manji HK, Quiroz JA, Sporn J, et al. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry. 2003;53(8):707-742.
57. Shimizu E, Hashimoto K, Okamura N, et al. Alterations of serum levels of brain-derived neurotrophic factor (BDNF) in depressed patients with or without antidepressants. Biol Psychiatry. 2003;54(1):70-75.
58. Tuglu C, Kara SH, Caliyurt O, Vardar E, Abay E. Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl). 2003;170(4):429-433.
59. Dupin N, Mailliet F, Rocher C, Kessal K, Spedding M, Jay TM. Common efficacy of psychotropic drugs in restoring stress-induced impairment of prefrontal plasticity. Neurotox Res. 2006;10(3-4):193-198.
60. Vermetten E, Vythilingam M, Southwick SM, Charney DS, Bremner JD. Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol Psychiatry. 2003;54(7):693-702.
61. Zavala F. Benzodiazepines, anxiety and immunity. Pharmacol Ther. 1997;75(3):199-216.
62. Oda T, Ueda A, Shimizu N, Handa H, Kasahara T. Suppression of monocyte chemoattractant protein 1, but not IL-8, by alprazolam: effect of alprazolam on c-Rel/p65 and c-Rel/p50 binding to the monocyte chemoattractant protein 1 promoter region. J Immunol. 2002;169(6):3329-3335.
63. Harter MC, Conway KP, Merikangas KR. Associations between anxiety disorders and physical illness. Eur Arch Psychiatry Clin Neurosci. 2003;253(6):313-320.
64. Gold PW, Licinio J, Wong ML, Chrousos GP. Corticotropin releasing hormone in the pathophysiology of melancholic and atypical depression and in the mechanism of action of antidepressant drugs. Ann N Y Acad Sci. 1995;771:716-729.
65. Stover E, Fenton W, Rosenfeld A, Insel TR. Depression and comorbid medical illness: the National Institute of Mental Health perspective. Biol Psychiatry. 2003;54(3):184-186.
66. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-370.
67. Bradesi S, Tillisch K, Mayer E. Emerging drugs for irritable bowel syndrome. Expert Opin Emerg Drugs. 2006;11(2):293-313.
68. Sairanen M, O'Leary OF, Knuuttila JE, Castren E. Chronic antidepressant treatment selectively increases expression of plasticity-related proteins in the hippocampus and medial prefrontal cortex of the rat. Neuroscience. 2007;144(1):368-374.
69. Tollefson GD, Tollefson SL, Pederson M, Luxenberg M, Dunsmore G. Comorbid irritable bowel syndrome in patients with generalized anxiety and major depression. Ann Clin Psychiatry. 1991;3(3):215-222.
70. Lydiard RB. The role of pharmacotherapy in panic disorder. In: Stein DJ, Hollander E, eds. The American Psychiatric Publishing Textbook of Anxiety Disorders. Washington, DC: American Psychiatric Press; 2002:257-272.
71. Camilleri M, Bueno L, de Ponti F, Fioramonti J, Lydiard RB, Tack J. Pharmacological and pharmacokinetic aspects of functional gastrointestinal disorders. Gastroenterology. 2006;130(5):1421-1434.